Intra-arterial gemcitabine extends PFS in locally advanced pancreatic cancer

Intra-arterial administration of gemcitabine conferred a median PFS benefit of 8 months when compared with standard of care for patients with locally advanced pancreatic cancer, according to results of the phase 3 TiGeR-PaC study.The findings, presented during ESMO World Congress on Gastrointestinal Cancer, also showed a 6-month median OS benefit with intra-arterial administration of gemcitabine (RenovoGem, RenovoRx) vs. systemic chemotherapy, according to a press release from the agent’s manufacturer.“Clinical practice has been waiting decades for a meaningful advancement in theRead More